In Brief: HK Medical Technologies' Autocath 100
This article was originally published in The Gray Sheet
HK Medical Technologies' Autocath 100: San Antonio firm obtains investigational device approval to begin enrollment of the first 60 patients in a long-term pivotal trial of its self-contained intraurethral bladder control device for treatment of female stress urinary incontinence. The approved protocol calls for treatment over two six-month periods. The silver-coated stainless steel Autocath is inserted by a physician and is anchored internally in the bladder as well as externally by a lower retention ring. Available in Europe since March 1997, the device is activated when an individual applies over a two-to-four second period abdominal pressure; the device closes when urine flow ends...
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.